Can a diabetes drug boost dialysis efficiency for kidney patients?
NCT ID NCT05671991
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if empagliflozin, a diabetes drug, can reduce sugar absorption during peritoneal dialysis in 30 adults with end-stage kidney disease. Participants will receive either the drug or a placebo in a crossover design, followed by an 8-week open-label phase where everyone gets the drug. The goal is to see if it helps dialysis work better by lowering glucose uptake.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE ON DIALYSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new graft keep dialysis access working longer?
- Could a Starch-Based drug clean toxins from dialysis Patients' blood?
- New dialysis fluid tested against standard in small study
- New study peers inside lungs during Clot-Busting procedure
- New pill could help dialysis patients control dangerous phosphate levels
- Tiny study tests diuretics for dialysis patients – terminated early